Krystal Biotech Prioritizes Inhaled KB707 for Non-Small Cell Lung Cancer Treatment

Krystal Biotech has prioritized inhaled KB707 for non-small cell lung cancer treatment, based on promising early evidence of efficacy. The company has paused enrollment in its OPAL-1 study for intratumoral KB707, but patients continue to be followed. Krystal Biotech is seeking FDA approval for inhaled KB707 and aims to bring a new therapeutic option to patients with NSCLC.

Krystal Biotech (NASDAQ: KRYS) has announced a strategic update for its oncology program KB707, focusing on the inhaled delivery method for treating non-small cell lung cancer (NSCLC). The company has secured an FDA End of Phase 2 meeting in October to discuss potential registration pathways for inhaled KB707 [1].

The decision follows promising clinical results presented at ASCO 2025, showing an objective response rate of 36% in heavily pre-treated NSCLC patients. The treatment demonstrated durability with median response and progression-free survival not yet reached. Importantly, inhaled KB707 showed a favorable safety profile with no Grade 4 or 5 adverse events [1].

As part of this prioritization, Krystal has paused enrollment in the OPAL-1 study for intratumoral KB707 while continuing the KYANITE-1 study for inhaled KB707 in lung tumors [1].

Krystal's inhaled KB707 shows promising 36% response rate in heavily pre-treated lung cancer patients, advancing toward potential FDA registration. The company's decision to pause enrollment in the OPAL-1 study (intratumoral delivery) to focus resources on the inhaled formulation indicates strong internal confidence in the inhaled approach and suggests a strategic prioritization of their pipeline based on clinical evidence rather than spreading resources across multiple delivery methods [1].

The mechanism of action of inhaled KB707 is particularly notable. By delivering IL-2 and IL-12 directly to lung tumors via inhalation, KB707 potentially achieves higher local concentration of these powerful immune stimulators while minimizing systemic toxicity—a common limitation of systemic immunotherapies. This localized approach could represent a meaningful advance in the treatment paradigm for NSCLC patients who have limited options after failing standard therapies [1].

The company's President of Research and Development, Suma Krishnan, stated, "The acceleration of our work on inhaled KB707 is a reflection of both the clear and acute unmet need that exists for new treatments of NSCLC and the promising efficacy profile we have observed to date with inhaled KB707. We look forward to meeting with the FDA and bringing another urgently needed therapeutic option to patients" [1].

Krystal Biotech is headquartered in Pittsburgh, Pennsylvania, and is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs [1].

References:
[1] https://www.stocktitan.net/news/KRYS/krystal-biotech-announces-update-on-development-plans-for-oncology-0he2506ngi71.html